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Abstract
Background: Data linkage studies find that depression before or after a breast cancer diagnosis pre-
dicts reduced survival. This study aimed to determine whether depression or bipolar recorded in rou-
tine hospital admission data independently predicts survival in English breast cancer patients and
whether onset in relation to cancer diagnosis is significant.
Methods: Data on 77 173 women diagnosed with breast cancer (ICD-10 C50) in South East England,
2000–2009, were included. Of these, 131 women had a diagnosis of bipolar affective disorder (ICD-10 F31)
and 955 of depression (either depressive episodes (ICD-10 F32) or depressive disorder (ICD-10 F33))
recorded in Hospital Episode Statistics between 3 years before and a year following cancer diagnosis.
Kaplan–Meier plots were used to examine overall survival. Cox regression analyses were carried out
overall and separately for mood disorder diagnoses before and after the cancer diagnosis and adjusted
for confounding variables.
Results: A record of depression was a predictor of worse overall survival in breast cancer patients
(adjusted HR=1.33, 95% CI: 1.20–1.48, p< 0.001), while the effect of bipolar was not statistically sig-
nificant (adjusted HR= 1.33, 95% CI: 0.97–1.82, p= 0.079). New recordings of depression and bipolar
diagnoses following a cancer diagnosis appeared better predictors of overall survival than a prior his-
tory of either.
Conclusions: There is evidence that English breast cancer patients with depression and bipolar re-
corded in routine hospital data have worse overall survival than those without these mood disorders.
Further work exploring the concordance of records within administrative health data with clinical di-
agnosis and cause-specific death within these patient groups is needed.
© 2015 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.
Background
For many years, patients and clinicians have been trying to
understand the link between physiological and psycholog-
ical health. Cancer patients often attribute psychological
factors to exceeding prognosis expectations, believing that
these play a key role in lengthening survival [1], but re-
search to support this is contradictory and inconclusive
[2–4].
Breast cancer is the most common cancer among women
in the UK, accounting for 30% of new cases of cancer in
women and affecting 49 936 women in 2011 [5]. Breast
cancer survival is determined by a number of factors in-
cluding age [6,7], comorbidity [8], socio-economic factors
and ethnicity [9,10], stage of the cancer at presentation [11]
and treatment [12,13].
Depression either prior to or post-breast cancer diagno-
sis has been shown to be a predictor of reduced survival
[4,14–17]. Researchers have suggested that this finding
may be due to patients with mood disorders presenting
at a later stage, receiving different treatments or having a
greater number of comorbidities [18–20]. However, stud-
ies adjusting for comorbidities have suggested that this is
not the case [21,22], raising the possibility that depression
may be an independent predictor of a worse prognosis.
One study in the Netherlands has also linked bipolar with
an increased risk of dying from cancer, although these
results were not statistically significant and length of sur-
vival was not reported [16]. As bipolar disorder has ele-
ments of both low mood (depression) and elevated mood
(mania), examining the association with breast cancer sur-
vival may help determine the mechanism of mood disor-
ders on cancer survival. Studies have also shown that
mental illnesses including bipolar disorder are a risk factor
for cancer onset [23,24]; with this suggested link in inci-
dence, it is thus important to establish its impact on
outcome.
Much research investigating the impact of mood disor-
ders on cancer survival has faced methodological limita-
tions, such as small sample sizes [14,15,17,25]. Many
studies have used cancer mortality as an outcome mea-
sure, making it hard to draw conclusions about the length
© 2015 The Authors. Psycho-Oncology Published by John Wiley & Sons Ltd.
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of survival after the diagnosis [17,20,26], and no studies
of bipolar disorder and breast cancer survival could be
identified. In addition, few studies have investigated the
timing of onset of the mood disorder in relation to the can-
cer diagnosis [14,22].
This study aims to determine whether mood disorders,
defined as depression or bipolar routinely recorded during
hospital admissions, are independent predictors of sur-
vival in breast cancer patients in South East England. It
also aims to determine whether the timing of the onset
of the disorder in relation to the cancer diagnosis is of
significance.
Methods
This study used cancer registration data collected for pa-
tients diagnosed with breast cancer between 2000 and
2009 and who were resident in the areas of London, Kent,
Surrey and Sussex in South East England covered by the
former Thames Cancer Registry (TCR). TCR received in-
formation from National Health Service (NHS) hospitals
about the clinical and pathological features of patients’
cancers and on the deaths of patients from the Office for
National Statistics via the NHS Central Register. Trained
cancer registration officers extracted further demographic
and tumour details, and information on the surgical, radio-
therapy and chemotherapy treatment patients received
within the first 6 months from medical records. Data re-
cords were quality assured as they were added to a central
database and duplicate cases eliminated. All inpatient and
day-case Hospital Episode Statistics (HES) episodes for
cancer patients were obtained from the Health and Social
Care Information Centre.
Hospital Episode Statistics data include information on
the clinical diagnoses of all patients admitted to English
NHS hospitals and are the basis of all analyses of hospital
activity and of contract payments made to hospitals for pa-
tient care. This information is based on the data entered to
the Patient Administration System in each hospital by
clinical coding staff, a short period after patients are
discharged. Coding staff undergo well-defined training to
be able to extract and code diagnoses using ICD-10 from
the clinical records. Coders do not make any inferences
about diagnoses but use only the information written in
the records and in typed discharge summaries by the re-
sponsible clinicians [27]. These data have been used to de-
scribe patterns of admission for adult psychiatric illness
[28], possible links between bipolar and physical illness
[29] and case finding for audits of dementia care [30]. A
systematic review of their accuracy has suggested that this
is improving because of a greater focus on payment and
increased understanding by clinicians of how the informa-
tion they include can be used [31]. These episodes were
linked to the registry data as part of the National Cancer
Data Repository using a rule-based linkage algorithm
based on NHS number, date of birth, sex, postcode of res-
idence and date of death.
All diagnoses listed in the HES episodes for the cancer
patients were examined. The mood disorders used in the
analysis were bipolar affective disorder (ICD-10 F31), at
least one depressive episode (ICD-10 F32) and recurrent
depressive disorder (ICD-10 F33) where these were re-
corded within HES in the 3 years before and the year fol-
lowing the cancer diagnosis. Diagnoses of mood disorders
were included regardless of the reason for the patient’s ad-
mission to hospital.
Breast cancer patients with any of the mental health
codes in the 4years specified were classified into two main
groups: ‘depression’ and ‘bipolar’. Patients with a diagno-
sis of either a recurrent depressive disorder or a depressive
episode were grouped together as ‘depression’ (n=955).
Of these patients, 422 had a prior record of a diagnosis
of depression, and 533 had a new record of depression
after the cancer diagnosis. Patients with a diagnosis of
bipolar were also grouped together in a ‘bipolar’ group
(n=131): 68 of these patients had a record of a diagnosis
before their cancer diagnosis, and 63 had a new record of
bipolar made after the cancer diagnosis. There were 94 pa-
tients who had a record of depression both before and after
their cancer diagnosis and 27 who had a record of bipolar
both before and after their cancer diagnosis.
Other variables included in the analysis were age at can-
cer diagnosis (which was grouped into 10-year age groups
from age 30 to 90years) and self-assigned ethnicity data
from HES data (categorized as White, Black, Asian,
Chinese/other and not known for this analysis). Based
on postcode of residence at cancer diagnosis, each patient
was assigned to a socio-economic deprivation quintile
using the income domain of the Indices of Deprivation
[32]. Information regarding stage of breast cancer at diag-
nosis was also included; TCR used a simple four-level
staging system, using information in the patients’ notes.
This allowed solid tumours to be assigned to categories
based on whether the disease (1) was local, (2) had direct
extension beyond the organ of origin, (3) had regional
lymph node involvement or (4) had metastasized. Treat-
ment given within 6 months of diagnosis including cancer
surgery, chemotherapy, radiotherapy and hormone ther-
apy was also considered.
Diagnostic codes within HES for admissions between
2 years before and 3 months after the cancer diagnosis
were also used to calculate Charlson comorbidity scores
[33] using a coding method developed by Quan et al.
[34]. These were aggregated into four categories for anal-
ysis ranging from 0 (no comorbid conditions) to 3 or more
(most severe). For this initial study, death from any cause
was chosen as the end point of interest. Historically, can-
cer registries have not captured information on date of re-
currence, nor is there an accepted method for defining this
from HES, making disease-free survival difficult to study.
20 R. Kanani et al.
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Statistical analyses
Survival rates 5 years after cancer diagnosis were calcu-
lated using the Kaplan–Meier method for patients with ei-
ther ‘depression’ or ‘bipolar’ compared with patients
without these mood disorders recorded. Cox regression
was used to estimate hazard ratios for patients with a re-
corded diagnosis of either ‘depression’ or ‘bipolar’. Fur-
ther Cox regression was used to find the estimated
hazard ratios for both ‘depression’ and ‘bipolar’ in relation
to timing of onset. These estimated hazard ratios were
then adjusted to account for the effect of confounders in-
cluding age, ethnicity, deprivation, comorbidities, stage
and recorded cancer treatment. We ran post-analysis
power calculations using stpower in Stata (StataCorp LP,
College Station, TX, USA) to determine the level of
power for the sample size and adjusted hazard ratios found
in the study, also taking into account the squared multiple-
correlation coefficient between the mood disorder variable
of interest and other variables in the model.
Results
There were 77 173 patients diagnosed with breast cancer
in South East England from 2000 to 2009. The numbers
of all breast cancer patients and those with a diagnosis
of depression or bipolar in each variable category are
shown in Table 1. Women with depression were most
likely to be aged over 70 years (37%), compared with all
breast cancer patients (32%) and women with a diagnosis
of bipolar (27%). Ethnicity information was more com-
plete in women with a depression or bipolar diagnosis.
However, even taking this into account, a higher propor-
tion of women in these groups were White. Women with
depression or bipolar were more likely to live in deprived
areas than all breast cancer patients. A lower proportion of
breast cancer patients with a diagnosis of depression had
no other comorbidity (65%) than those with a diagnosis
of bipolar (73%) or all breast cancer patients (72%, or
87% of those where a comorbidity score was known).
The stage of disease at diagnosis was very similar in the
three groups, with 7–8% of patients with metastatic dis-
ease. Recorded treatment was also similar across the
groups, although women with depression were slightly
less likely to receive different treatment modalities than
all breast cancer patients.
Figure 1 shows that patients with depression had worse
survival than patients without depression, with 55% of pa-
tients with a record of depression alive 5 years after their
cancer diagnosis compared with 75%without depression re-
corded. Figure 2 shows that patients with a record of a diag-
nosis of bipolar had initially had similar survival than those
without. However, from 2 years after diagnosis, bipolar pa-
tients had worse survival, with a 5-year survival of 64%
compared with 74% in patients without a bipolar diagnosis.
Table 1 shows that patients with a record of depression
before or following the breast cancer diagnosis had a
higher risk of dying even after adjusting for age, ethnicity,
deprivation, comorbidities, stage of disease and treatment
(fully adjusted HR=1.33, 95% confidence interval (CI):
1.20–1.48, p<0.001). The timing of the onset of depres-
sion appeared to be important. Depression recorded prior
to the cancer diagnosis had a high unadjusted hazard ratio
of 2.29 (95% CI: 1.98–2.64, p<0.001) (Table 2), but this
reduced to 1.23 (95% CI: 1.07–1.42, p=0.005) after
adjustment, with the main attenuating factors being age,
comorbidity and stage. Depression after the cancer diag-
nosis, when no previous history of depression had been re-
corded, demonstrated a high hazard ratio of 1.69 (95% CI:
1.46–1.95, p<0.001) but was less affected by adjustment
(HR=1.45, 95% CI: 1.25–1.68, p<0.001).
Table 1 also shows that patients with a record of bipolar
had an increased risk of death compared with breast
Figure 1. Kaplan–Meier survival for breast cancer patients with
and without a record of a diagnosis of depression, South East
England, 2000–2009
Figure 2. Kaplan–Meier survival for breast cancer patients with
and without a record of a diagnosis of bipolar, South East England,
2000–2009
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cancer patients without (HR=1.37, 95% CI: 1.00–1.88,
p=0.049). This association was slightly attenuated and
not statistically significant after adjustment, partly because
of the small numbers of patients in these groups. The main
attenuating factors for bipolar were deprivation, comor-
bidities and treatment. There was no statistically signifi-
cant association with survival and a pre-cancer diagnosis
of bipolar (fully adjusted HR=1.20, 95% CI: 0.79–1.82,
p=0.402) (Table 2). The hazard ratio for post-cancer on-
set of bipolar increased after adjustment but also did not
reach statistical significance (unadjusted HR=1.37, 95%
CI: 0.85–2.20, p=0.197, to fully adjusted HR=1.54,
95% CI: 0.96–2.48, p=0.075).
There was high power for all the adjusted depression
and post-cancer depression variables (both 0.99), while
adjusted pre-cancer depression had power of 0.59. All
the adjusted bipolar results had low power (0.39, 0.12
and 0.43 for all bipolar, pre-cancer and post-cancer bipo-
lar, respectively).
Conclusions
Summary of main findings
This study of linked cancer registration and hospital ad-
mission data for 77 173 women diagnosed with breast
cancer between 2000 and 2009 found that mood disorders
appear to indicate worse survival in breast cancer patients.
Depression was a clear predictor of reduced survival in
breast cancer patients, whereas bipolar showed indications
of a similar effect that was not statistically significant. Mood
disorders with an onset after the breast cancer diagnosis
were more strongly associated with reduced survival than
a previous medical history of either depression or bipolar.
Comparison of findings with previous research
Previous research looking solely at the link between de-
pression and breast cancer survival has produced greater
hazard ratios for depression in breast cancer patients than
observed in this study [14,35,36], although these were
sometimes underpowered and not statistically significant.
Some previous research, however, conflicts with our find-
ings by suggesting no effect of depression on breast can-
cer survival [15,37]. These differences may be due to the
smaller sample sizes and variation in the inclusion and di-
agnostic criteria used.
Conversely, a meta-analysis of 12 independent studies
analysing the impact of depression on survival of different
types of cancer [4] reported a lower but statistically signif-
icant adjusted hazard ratio (1.09 compared with 1.33 in this
study). Another meta-analysis examining depression and
cancer mortality also found a significant association in
breast cancer patients [38]. The findings of our study that
the worse survival cannot be solely attributed to later stage
of presentation are also similar to others [21,22,26,39].
Our finding of worse survival in patients with bipolar is
in line with that of Guan et al. [16] who found increased
cancer mortality in these patients but not with that of a
larger study by Osby et al. [40].
Possible explanations for the link between depression
and worse survival include the biological and personal im-
pact of depression. Depression has been linked to a
chronic activation of the hypothalamic–pituitary–adrenal
axis, which can affect the cellular immune system [41–43].
In addition, abnormalities in diurnal cortisol rhythms [44]
have been associated with worse survival. Disruptions to im-
mune and endocrine functions may therefore be mediators of
a more rapid disease progression and higher cancer-related
mortality.
Depression could also influence coping styles, behav-
iour and lifestyle choices with studies reporting an associ-
ated increase in risk of relapse or death [45]. Patients with
depression are characteristically less motivated and have a
reduced level of self-care, which has been linked to poorer
compliance with treatment [22,46]. Studies suggest that
these patients receive suboptimal treatment and increased
waiting times as clinicians face obstacles with eliciting
capacity and encouraging uptake and compliance
[22,26,47]. This may be in line with our findings that
cancer surgery, radiotherapy and chemotherapy utilization
in patients with depression was slightly lower than that
in all breast cancer patients, with studies demonstrating
their role in reducing recurrence and breast cancer mor-
tality [48,49]. However, without more in-depth clinical
information about the patients’ cancer and their manage-
ment plans, it is difficult to make assumptions that these
patients received suboptimal care. Clinicians also have
to adjust cancer treatment because of the contraindica-
tions and interactions with the medication patients may
be taking for their mental illness, as well as their in-
creased number of comorbidities [20]. Depression is
also associated with somatic symptoms including fatigue,
decreased appetite and pain, all of which are determinants
of quality of life, an independent predictor of patient prog-
nosis [50].
Depression onset after cancer diagnosis was more
strongly associated with worse survival than a prior diag-
nosis of depression. This could be explained if these diag-
noses represent those that were not detected, managed and
controlled earlier and may therefore have had a more pro-
found impact on health behaviours, lifestyle choices, and
treatment uptake and compliance. These could also be
cases previously attributed to low-mood symptoms ‘ex-
pected’ after a cancer diagnosis [51].
Both depression and bipolar have been linked to higher
suicide rates and unhealthier lifestyles including smoking
and alcohol intake – which are risk factors for reduced sur-
vival [40]. These factors and the low-mood component of
bipolar may explain the trend that we noticed between bi-
polar and breast cancer survival.
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Strengths and limitations
This linkage study has a larger sample size than many
others in this field and is the first to be carried out on
breast cancer using routine hospital data in England and
to investigate the impact of bipolar. This study was also
able to take into account many potential confounders:
age, deprivation, ethnicity, comorbidities, disease stage
at presentation and recorded cancer treatment. There were
several tumour factors that were not available to include in
the study, including oestrogen receptor, progesterone recep-
tor and HER-2 status; performance status; or more detailed
staging information. Some variables also had incomplete in-
formation: staging information (28%), ethnicity (24%) and
comorbidity (17%).
The main limitations relate to potential deficits in the re-
cording and coding of depression and bipolar in routine
hospital data. Patients who were not admitted as inpatients
or day cases and those whose depression or bipolar diag-
noses were not recorded as clinically relevant or went un-
noticed would not be included as having a mood disorder
in the analyses. Symptoms of low mood, disinterest, fa-
tigue and reduced energy may be common in cancer pa-
tients, and the nonspecific nature of the symptoms of
depression (particularly the somatic symptoms) makes it
hard to distinguish from side effects of treatment like che-
motherapy [51]. A review by Fann et al. [52] suggested
that estimates of depression rates in breast cancer patients
who had received surgery varied between 10% and 25%.
Studies have reported the issues of under-recognition
and poor oncologist–patient agreement regarding levels
of depression [53], which may explain the lower preva-
lence of depression in the patient population in this study
than in the general population. It could be that only the
most severely affected patients were therefore included
in this analysis. While these cases would be likely to have
the greatest impact on survival, the exclusion of other
cases may have underestimated the full effect.
The sample size of patients with mood disorders is quite
small, partly reflecting the relative rarity of the disease and
the way these patients were identified, limiting the study’s
power. The low power for the bipolar analyses suggests
that there may be an effect on survival that we did not
have a large enough sample to detect. The association be-
tween bipolar and survival in breast cancer patients cannot
be ruled out from this study, and indeed, the hazard ratios
suggest there may be a similar effect to depression.
Cumulative effects of recurrent episodes or of both de-
pressive and bipolar episodes could also not be investi-
gated. Information on a number of confounders was not
available and therefore not adjusted for including lifestyle
factors such as smoking status, body mass index, alcohol
consumption, treatment for mood disorders, waiting times
and social support. Another limitation is the endpoint of
cause of death, which in this initial study was not
cancer-specific deaths, and the reduction in survival may
be linked to the behavioural patterns associated with de-
pression including unhealthy lifestyle, suicide and the
higher risk of other comorbidities. Thus, the reduction in
survival may be due to the reduced survival in patients
with depression or bipolar, regardless of their cancer diag-
nosis. From a clinical perspective, if the reduced survival
is not cancer specific, it still indicates a need for interven-
tion from a psychiatric and social support perspective.
Death certificate data on immediate cause of death can
vary between providers, but further careful analysis of
these factors would shed light on their possible contribu-
tion to the earlier deaths found here. Examining length
of disease free survival would also be of interest.
Further research
Further research using cancer registration and hospital
data for the rest of England should increase the number
of patients with mood disorders and allow more in-depth
analysis of groups of patients with isolated or recurrent
depressive episodes and the predominantly depressive or
manic bipolar patterns. Analysis of patients by different
cancer stage and the treatment they received from differ-
ent mental health specialists would also be possible with
larger numbers of patients. Linkage to general practice
data has the potential to capture diagnoses made outside
hospital and with wider clinical severity, and it would be
interesting to see if the same results can be demonstrated
for male patients with breast cancer. Studies of the reliability
of the diagnostic coding of depression based on clinician
assessment compared with validated scales or standardized
interviews would also be an important next step.
Further analysis of patients diagnosed with depression
or bipolar after treatment has ended may also be informa-
tive. Studies show that patients can develop depression
because of fears of recurrence, adjusting to the physical re-
sults of surgery [54] and lack of focus once treatment has
ended [55]. Some medical professionals and family may
reduce their support if they do not appreciate that comple-
tion of medical treatment does not necessarily mean full
recovery [55,56]. A separate analysis of patients with a
cancer-specific death may be useful to determine whether
the reduced survival is due to the impact of depression on
cancer progression or depression on general survival. It
may also be possible to investigate disease-free survival
as better information becomes available through recent
expansion of information captured by the National Cancer
Registration Service.
Implications for practice
The results from this study could imply that it is the low-
mood aspect of a mood disorder that results in worse sur-
vival rather than a general mood disturbance. This may
explain why bipolar was not a clear indicator of survival,
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and results yielded were largely inconclusive. Increased
clinical awareness of depression to prevent under-
diagnosis and to direct possible interventions may be ben-
eficial irrespective of whether depression directly impacts
on survival or affects survival through its impact on cancer
progression. A more active approach to cancer screening
and establishing treatment guidelines for patients with
mood disorders may also target inequalities in uptake
and utilization of these services. Introducing social support
or psychological interventions for breast cancer patients
from more deprived socio-demographic backgrounds,
older age groups and those presenting with a larger number
of comorbidities may target those most at risk and limit or
avoid the detrimental effects of depression in these
patients.
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